APA (7th ed.) Citation

Ghofrani, H. A., & Grünig, E. (2017). Riociguat for the treatment of pulmonary arterial hypertension (PAH): 2-year results from the PATENT-2 long-term extension. BMC pharmacology & toxicology, 18, . https://doi.org/10.1186/s40360-017-0170-5

Chicago Style (17th ed.) Citation

Ghofrani, Hossein Ardeschir, and Ekkehard Grünig. "Riociguat for the Treatment of Pulmonary Arterial Hypertension (PAH): 2-year Results from the PATENT-2 Long-term Extension." BMC Pharmacology & Toxicology 18 (2017). https://doi.org/10.1186/s40360-017-0170-5.

MLA (9th ed.) Citation

Ghofrani, Hossein Ardeschir, and Ekkehard Grünig. "Riociguat for the Treatment of Pulmonary Arterial Hypertension (PAH): 2-year Results from the PATENT-2 Long-term Extension." BMC Pharmacology & Toxicology, vol. 18, 2017, https://doi.org/10.1186/s40360-017-0170-5.